Royalty Pharma
RPRX
RPRX
333 hedge funds and large institutions have $10.9B invested in Royalty Pharma in 2023 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 143 increasing their positions, 98 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
0.18% more ownership
Funds ownership: 67.82% → 68.01% (+0.18%)
1% less funds holding
Funds holding: 335 → 333 (-2)
8% less capital invested
Capital invested by funds: $11.8B → $10.9B (-$935M)
Holders
333
Holding in Top 10
10
Calls
$37.9M
Puts
$3.16M
Top Buyers
| 1 | +$82.9M | |
| 2 | +$64.8M | |
| 3 | +$43.8M | |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$43.1M |
| 5 |
Goldman Sachs
New York
|
+$39M |
Top Sellers
| 1 | -$149M | |
| 2 | -$120M | |
| 3 | -$78.2M | |
| 4 |
Morgan Stanley
New York
|
-$68.3M |
| 5 |
HSBC Holdings
London,
United Kingdom
|
-$27.1M |